CATALYST PHARMACEUTICALS, INC.CPRXEarnings & Financial Report
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Fir...
Revenue
$141.4M
Gross Profit
$123.5M
Operating Profit
$63.4M
Net Profit
$56.7M
Gross Margin
87.3%
Operating Margin
44.8%
Net Margin
40.1%
YoY Growth
43.6%
EPS
$0.45
CATALYST PHARMACEUTICALS, INC. Q1 FY2025 Financial Summary
CATALYST PHARMACEUTICALS, INC. reported revenue of $141.4M (up 43.6% YoY) for Q1 FY2025, with a net profit of $56.7M (up 143.8% YoY) (40.1% margin). Cost of goods sold was $17.9M, operating expenses totaled $60.1M.
Key Financial Metrics
| Total Revenue | $141.4M |
|---|---|
| Net Profit | $56.7M |
| Gross Margin | 87.3% |
| Operating Margin | 44.8% |
| Report Period | Q1 FY2025 |
Revenue Breakdown
CATALYST PHARMACEUTICALS, INC. Q1 FY2025 revenue of $141.4M breaks down across 3 segments, led by Firdapse at $83.7M (59.2% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Firdapse | $83.7M | 59.2% |
| Fycompa | $35.6M | 25.2% |
| Agamree | $22.0M | 15.6% |
CATALYST PHARMACEUTICALS, INC. Revenue by Segment — Quarterly Trend
CATALYST PHARMACEUTICALS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Firdapse and Fycompa) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Firdapse | $97.6M | $92.2M | $84.8M | $83.7M |
| Fycompa | $19.6M | $23.8M | $34.3M | $35.6M |
| Agamree | $35.3M | $32.4M | $27.4M | $22.0M |
CATALYST PHARMACEUTICALS, INC. Annual Revenue by Year
CATALYST PHARMACEUTICALS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $589.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $589.0M |
| 2024 | $491.7M |
CATALYST PHARMACEUTICALS, INC. Quarterly Revenue & Net Profit History
CATALYST PHARMACEUTICALS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $152.6M | +7.6% | $52.7M | 34.5% |
| Q3 FY2025 | $148.4M | +15.3% | $52.8M | 35.6% |
| Q2 FY2025 | $146.6M | +19.4% | $52.1M | 35.6% |
| Q1 FY2025 | $141.4M | +43.6% | $56.7M | 40.1% |
| Q4 FY2024 | $141.8M | +28.3% | $55.9M | 39.4% |
| Q3 FY2024 | $128.7M | +25.3% | $43.9M | 34.1% |
| Q2 FY2024 | $122.7M | +23.2% | $40.8M | 33.2% |
| Q1 FY2024 | $98.5M | +15.4% | $23.3M | 23.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $98.5M | $122.7M | $128.7M | $141.8M | $141.4M | $146.6M | $148.4M | $152.6M |
| YoY Growth | 15.4% | 23.2% | 25.3% | 28.3% | 43.6% | 19.4% | 15.3% | 7.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $646.7M | $706.4M | $772.0M | $851.4M | $908.9M | $971.9M | $1.05B | $1.10B |
| Liabilities | $85.3M | $97.7M | $111.1M | $123.8M | $114.6M | $115.9M | $131.4M | $149.7M |
| Equity | $561.4M | $608.7M | $660.9M | $727.6M | $794.3M | $856.0M | $920.2M | $954.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $31.9M | $64.1M | $72.9M | $70.9M | $60.0M | $71.3M | $32.4M | $44.9M |